MK-677 (Ibutamoren): An Orally Active Non-Peptide Ghrelin Receptor Agonist

Research summary. MK-677 (development code MK-0677, also known as ibutamoren and L-163,191) is an orally bioavailable, long-acting ghrelin receptor (growth hormone secretagogue receptor 1a, GHSR-1a) agonist. Unlike the peptide secretagogues GHRP-2, GHRP-6, hexarelin, and ipamorelin, MK-677 is a non-peptide spiropiperidine small molecule. It was developed at Merck in the 1990s as part of a programme to identify orally active growth-hormone-secretagogue compounds and reached substantial clinical-trial development for sarcopenia, cachexia, and growth hormone deficiency before being discontinued from advanced clinical use.

Molecular profile

• Class: Spiropiperidine-class non-peptide growth hormone secretagogue (ghrelin receptor / GHSR-1a agonist)
• Molecular formula: C₂₇H₃₆N₄O₅S
• Molecular weight: ~528.7 g/mol
• PubChem CID: 9939050
• CAS Number: 159634-47-6
• Synonyms: MK-0677, ibutamoren, L-163,191, oratrope (trade-name in some research literature)
• Note: MK-677 is not a peptide and not a SARM — both miscategorisations appear regularly in non-research literature.

Mechanism of action

MK-677 is a high-affinity, orally bioavailable agonist at GHSR-1a, the receptor through which the endogenous peptide ghrelin acts. Binding mimics the action of ghrelin on hypothalamic and pituitary GHSR-1a-expressing neurons, producing:

• Pulsatile growth hormone (GH) release from the anterior pituitary, with preservation of the normal pulsatile pattern of GH secretion.
• Downstream IGF-1 elevation via hepatic IGF-1 production driven by the elevated GH exposure.
• Cortisol and prolactin profiles largely preserved at therapeutic doses in published studies, distinguishing MK-677 from older non-selective GH secretagogues.
• Appetite stimulation, consistent with the orexigenic activity of native ghrelin signalling.

The oral bioavailability and ~24-hour duration of action are the key pharmacokinetic features that distinguish MK-677 from the peptide GHSR agonists (GHRP-2, GHRP-6, hexarelin, ipamorelin), which require parenteral administration and have much shorter durations.

Clinical research highlights

Healthy older adults — body composition. A 2-year placebo-controlled clinical trial in healthy older adults reported that daily oral MK-677 produced sustained elevations in GH and IGF-1, modest gains in fat-free mass, and changes in body composition without significant strength gains [1]. This trial is the most extensively cited human dataset for MK-677 and remains a standard reference for the compound's bioactivity profile.

Hip-fracture recovery. Published clinical work has reported that MK-677 administered to older adults recovering from hip fracture produced increases in IGF-1 and modest functional changes; clinical-endpoint outcomes were not strong enough to support an approval pathway in this indication.

Growth hormone deficiency and provocative testing. MK-677 has been studied as a provocative test for GH reserve and as an oral alternative to injectable GH-axis stimulation in GH-deficiency research contexts.

Sleep architecture. Clinical work has reported increases in REM and Stage 4 (slow-wave) sleep with MK-677 administration in younger and older adults, consistent with the broader association between GH-axis activity and sleep architecture.

Adverse-event profile. Reported effects include increased appetite, transient lower-extremity oedema, mild blood-glucose increases, transient muscle/joint discomfort, and mild lethargy. Insulin sensitivity changes and oedema are the most commonly cited tolerability concerns in the literature.

Why MK-677 was not approved

Despite extensive development, MK-677 did not advance to FDA approval in any indication. The reported effects on lean mass and IGF-1 were not matched by demonstrated improvements in clinically meaningful functional endpoints (strength, falls, mortality) sufficient to support an approval pathway. This pattern — robust biomarker effect without proportional clinical-endpoint benefit — is a recurring feature of GH-axis-targeting development programmes and is part of the reason most research-supplier MK-677 sits in an investigational rather than approved category.

Current research status

MK-677 is an investigational research compound. It is not approved by the FDA for any indication. Research interest continues across sarcopenia, cachexia, GH-deficiency mechanism studies, and as a tool molecule in ghrelin-receptor pharmacology.

For research-supplier contexts, MK-677 is supplied as a research-grade investigational compound and is not intended for self-administration.

Key takeaways for researchers

• MK-677 (ibutamoren, L-163,191) is a non-peptide, orally bioavailable spiropiperidine ghrelin receptor (GHSR-1a) agonist.
• It produces sustained pulsatile GH release and downstream IGF-1 elevation with a ~24-hour duration of action.
• A 2-year clinical trial in older adults reported sustained GH/IGF-1 elevation and modest body-composition changes without significant strength gains.
• Common reported adverse effects include increased appetite, oedema, and modest changes in insulin sensitivity.
• MK-677 is not an FDA-approved drug; it is sometimes miscategorised as a SARM or as a peptide and is neither.

References

1. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 1999;14(7):1182–1188.
2. Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. PNAS. 1995;92(15):7001–7005.

---

This article is provided for educational and research purposes only. MK-677 is a research compound. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this compound should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.